Fosun International’s Alnylam Pharmaceuticals ALNY Stock Holding History

Fosun International’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,730	Closed	-$483K	–	46
2023 Q3	$483K	Hold	2,730	–	–	0.08%	54
2023 Q2	$519K	Hold	2,730	–	–	0.07%	50
2023 Q1	$547K	Buy	+2,730	New	+$574K	0.05%	51
2019 Q3	–	Sell	-54,300	Closed	-$3.86M	–	232
2019 Q2	$3.86M	Buy	54,300 +6,000	+12%	+$460K	0.25%	59
2019 Q1	$4.38M	Hold	48,300	–	–	0.28%	50
2018 Q4	$3.31M	Buy	48,300 +11,800	+32%	+$908K	0.2%	58
2018 Q3	$3.29M	Buy	+36,500	New	+$3.67M	0.16%	64

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Fosun International's ALNY Position: Q4 2023 in Review

Fosun International sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2023, closing a stake of 2,730 shares — an estimated $483K sold.

Fosun International first reported a position in ALNY in Q3 2018 and held it in 7 quarters. The position peaked at $4.38M in Q1 2019. 499 funds tracked by Wall St. Rank hold ALNY as of Q4 2023.

Fosun International reported no remaining Alnylam Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Fosun International sold 2,730 Alnylam Pharmaceuticals shares in Q4 2023, an estimated $483K.
Fosun International first reported a position in Alnylam Pharmaceuticals in Q3 2018 and held it in 7 quarters.
Fosun International's Alnylam Pharmaceuticals position peaked at $4.38M in Q1 2019.
499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2023.

Based on Fosun International's 13F filing for Q4 2023, filed 7 Feb 2024.